All In Biotech

Drug Trial Radar · NCT04336241

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Oct 17, 2019

Primary completion

Oct 31, 2026

Study completion Oct 31, 2026

Sponsor

Lead sponsor
Replimune, Inc.Industry
Sponsor type
Industry
First posted
Apr 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RP2-001-18 is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP2 in adult subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

Conditions

  • Cancer

Interventions

  • RP2Biological

    Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation

  • nivolumabBiological

    Programmed death receptor (PD-1) blocking antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of adverse events (AEs)Time frame: From Day 1 up to 60 days after last dose
  2. Percentage of serious adverse events (SAEs)Time frame: From Day 1 up to 60 days after last dose
  3. Percentage of dose limiting toxicities (DLTs)Time frame: From Day 1 up to 30 days after last dose.
  4. Percentage of treatment emergent adverse events (TEAEs)Time frame: From Day 1 up to 60 days after last dose.
  5. Percentage of TEAEs ≥ Grade 3Time frame: From Day 1 up to 60 days after last dose.
  6. Percentage of events requiring withdrawalTime frame: From Day 1 up to last dose (up to 8 weeks for dose escalation phase and up to 2 years for expansion phase)).
  7. Maximum tolerated dose (MTD) of RP2Time frame: 7 months
  8. Recommended Phase 2 dose (RP2D) of RP2Time frame: 7 months

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Hospital Universitario d'Hebron

    Barcelona, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain

  • Hospital Clinico de Valencia

    Valencia, Spain

  • The Royal Marsden NHS Foundation Trust

    London, United Kingdom

  • Churchill Hospital

    Oxford, United Kingdom

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    Bebington, Merseyside, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.